Diagnostic microbiology and infectious disease最新文献

{"title":"Delafloxacin and levofloxacin activities on Helicobacter pylori in Bulgaria over four years","authors":"Lyudmila Boyanova ,&nbsp;Victor Kamburov ,&nbsp;Nayden Kandilarov ,&nbsp;Nikolay Katsarov ,&nbsp;Petyo Hadzhiyski ,&nbsp;Liliya Yordanova Boyanova ,&nbsp;José Medeiros ,&nbsp;Raina Gergova ,&nbsp;Galina Gergova ,&nbsp;Rumyana Markovska","doi":"10.1016/j.diagmicrobio.2025.117012","DOIUrl":"10.1016/j.diagmicrobio.2025.117012","url":null,"abstract":"<div><div>Delafloxacin is a potent 4th-generation fluoroquinolone with enhanced activity in acidic environments. However, recently, delafloxacin resistance in facultative anaerobic species has been reported. Thus, we examined levofloxacin and delafloxacin susceptibility of 98 <em>Helicobacter pylori</em> strains in 2020-2023. Minimum inhibitory concentrations (MICs) were detected with E tests. Levofloxacin resistance was 33.7%, while delafloxacin resistance was 2.0% at 1 mg/l (the levofloxacin resistance breakpoint for <em>H. pylori</em>), and 9.2% at 0.125 mg/l (the recently suggested delafloxacin ECOFF for the species). Overall proportion of the strains exhibiting &gt;0.125 mg/l delafloxacin MICs was similar to that in the previous study in 2018-2019 (8.5%). None of the 65 levofloxacin susceptible strains had delafloxacin MICs of &gt;0.125 mg/l. Among levofloxacin resistant strains, delafloxacin MICs &gt;1 mg/l (6.1%, 2/33 strains) were detected only in 2022 and 2023. Briefly, the results showed the much higher activity of delafloxacin over levofloxacin. The high delafloxacin activity in acidic environments is an additional advantage of the newer fluoroquinolone for treating <em>H. pylori</em> infection. Given that fluoroquinolone-based eradication regimens can be used as a second- or third-line therapy for <em>H. pylori</em>, testing the susceptibility of levofloxacin-resistant strains to delafloxacin could provide a useful option for eradication of the frequent and potentially carcinogenic bacteria. New regimens, such as the combination of vonoprazan with delafloxacin and another antibiotic deserve investigation.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117012"},"PeriodicalIF":2.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144672198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polymorphisms of the CYP2D6 gene and its relationship with Plasmodium vivax relapses after chloroquine-primaquine treatment in Turbo, Colombia","authors":"Veronica Sierra-Cifuentes ,&nbsp;Lina Zuluaga-Idárraga ,&nbsp;Daniel Aguirre-Acevedo ,&nbsp;Maria Carolina Silva de Barros Puça ,&nbsp;Tais Nobrega de Sousa ,&nbsp;Tatiana M. Lopera-Mesa","doi":"10.1016/j.diagmicrobio.2025.117013","DOIUrl":"10.1016/j.diagmicrobio.2025.117013","url":null,"abstract":"<div><h3>Background</h3><div><em>Plasmodium vivax</em> relapse due to hypnozoites represents a significant mechanism for parasite persistence in the population. Primaquine (PQ), the drug of choice for eliminating hypnozoites, requires metabolic activation by Cytochrome P450-2D6 (CYP2D6). Genetic variations in <em>CYP2D6</em> can alter PQ metabolism, potentially increasing the risk of relapses. This study aimed to determine <em>CYP2D6</em> polymorphisms in subjects with <em>Plasmodium vivax</em> under supervised chloroquine-primaquine treatment and explore their association with relapses and PQ plasma levels.</div></div><div><h3>Methods</h3><div><em>CYP2D6</em> phenotypes and genotypes were successfully determined for 71 out of 78 patients included in the study. Nine polymorphisms (SNPs and indels) and gene copy number variation were analyzed. The association between the <em>CYP2D6</em> phenotype, <em>P. vivax</em> relapse over six months follow-up, and PQ plasma levels were explored.</div></div><div><h3>Results</h3><div>Most diplotypes (81.7 %) were associated with normal (gNM-F) and ultrarapid (gUM) CYP2D6 metabolizers, while 18.3 % were associated with poor (gPM) and intermediate (gIM and gNM-S) metabolizers. The median plasma PQ concentration on day 2 was higher in impaired CYP2D6 activity group (poor/intermediate) compared normal metabolizers (normal/ultrarapid) (660.4 ng/ml vs 313.5 ng/ml; effect size r -0.51, 95 % CI -0.82 to 0.03). No significant difference was found in the hazard ratio (HR) of relapse between impaired and normal CYP2D6 activity (adjusted HR: 1.45; 95 % CI: 0.39–5.39).</div></div><div><h3>Conclusion</h3><div>Impaired <em>CYP2D6</em> activity phenotypes were frequent in individuals infected with <em>P. vivax</em> from an endemic region of Colombia. Further research is essential to elucidate the relationship between these phenotypes and <em>P. vivax</em> relapses, as suggested by this exploratory study.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117013"},"PeriodicalIF":2.1,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144680604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surveillance of multidrug resistant methicillin-resistant and Panton-Valentine leukocidin positive Staphylococcus aureus in healthy carriers in Lambaréné, Gabon","authors":"Christiane Sidonie Gouleu ,&nbsp;Tobias Grebe ,&nbsp;Guy Arnault Rogue Mfoumbi Ibinda ,&nbsp;Viktoria Rudolf ,&nbsp;Bayode Romeo Adegbite ,&nbsp;Jean Ulrich Muandze-Nzambe ,&nbsp;Marina H. Biteghe Nsole ,&nbsp;Augustin B. Boueya ,&nbsp;Bertrand Lell ,&nbsp;Matthew Benjamin Bransby McCall ,&nbsp;Peter Gottfried Kremsner ,&nbsp;Abraham Sunday Alabi ,&nbsp;Frieder Schaumburg ,&nbsp;Ayola Akim Adegnika","doi":"10.1016/j.diagmicrobio.2025.117009","DOIUrl":"10.1016/j.diagmicrobio.2025.117009","url":null,"abstract":"<div><div>We assessed the prevalence of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) colonization in humans from both hospital and community settings in Gabon. The rate of MRSA was 18 % with no significant difference between healthcare and community members. We observed a remarkedly high prevalence of PVL (42 %) and MDR (83 %) among MRSA isolates.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117009"},"PeriodicalIF":2.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144665574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam and cefepime-zidebactam activities on a wide collection of French clinical Enterobacterales isolates","authors":"Camille Petillon ,&nbsp;Mauli Ululuipalelei ,&nbsp;Racha Beyrouthy ,&nbsp;Simon Proust ,&nbsp;Nejla Aissa ,&nbsp;Laurent Bret ,&nbsp;Nathalie Brieu ,&nbsp;Anne Carricajo ,&nbsp;Vincent Cattoir ,&nbsp;Olivier Dauwalder ,&nbsp;Nicolas Degand ,&nbsp;Laurent Dortet ,&nbsp;Florence Doucet-Populaire ,&nbsp;Véronique Dubois ,&nbsp;Antoine Grillon ,&nbsp;François Guérin ,&nbsp;Philippe Lanotte ,&nbsp;Nadine Lemaitre ,&nbsp;David Leyssene ,&nbsp;Catherine Neuwirth ,&nbsp;Frédéric Robin","doi":"10.1016/j.diagmicrobio.2025.117011","DOIUrl":"10.1016/j.diagmicrobio.2025.117011","url":null,"abstract":"<div><div>In recent years, novel β-lactam-inhibitor combinations (imipenem-relebactam (I/R), meropenem-vaborbactam (M/V), aztreonam-avibactam (A/A)) have been commercialized and some are not yet on the market (cefepime-zidebactam (C/Z)). The objective of this study was to evaluate the efficacy of these β-lactam-β-lactamase inhibitors (BL/BLIs) combinations against a wide collection of French clinical multiresistant <em>Enterobacterales</em> isolates and to assess the performance of the E-test MIC method for I/R and M/V.</div><div>BL/BLIs MICs were determined by broth microdilution on a collection of 200 ESBL-producing and 414 carbapenem-resistant clinical <em>Enterobacterales</em> (<em>K. pneumoniae</em> (271), <em>E. coli</em> (245), <em>E. cloacae complex</em> (48), other <em>species</em> (50)) including 292 carbapenemase-producing isolates. E-test method was evaluated for the determination of I/R and M/V MICs using 131 isolates from this collection.</div><div>All the combinations were active against most ESBL-producing isolates (99-100 %), but C/Z and A/A MIC90 were lower than that of I/R and M/V (2mg/L and 2mg/L <em>versus</em> 8mg/L and 8mg/L). The M/V and I/R E-tests performances were close to those required by the FDA recommendations: Categorical agreement (CA) and Essential agreement (EA) ≥ 90 %, Major discrepancy (MD) and Very major discrepancy (VMD) &lt; 3 %): 96.9 % (CA), 92.4 % (EA), 1.2 % (MD), 6.1 % (VMD) for I/R and 94.7 % (CA), 96.9 % (EA), 4.1 % (MD), 8.8 % (VMD) for M/V.</div><div>This work confirmed the interest of C/Z and A/A combinations against carbapenem-resistant <em>Enterobacterales</em> isolates compared with M/V and I/R. Additionally, the findings indicate that the E-test method can be used for the determination of M/V and I/R MIC for <em>E. coli</em> and <em>K. pneumonia</em>e strains.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117011"},"PeriodicalIF":2.1,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum VEGF-A and sVEGFR-1 levels as predictors of disease severity in COVID-19 patients","authors":"Sevgi Baltacı ,&nbsp;Mehmet Bakır","doi":"10.1016/j.diagmicrobio.2025.117007","DOIUrl":"10.1016/j.diagmicrobio.2025.117007","url":null,"abstract":"<div><h3>Background</h3><div>The pathogenesis of COVID-19 highlights the pivotal role of endothelial dysfunction and dysregulated angiogenic signaling. Vascular endothelial growth factor A (VEGF-A) and its soluble receptor (sVEGFR-1) are critical regulators of vascular integrity. This study aimed to investigate the association between serum VEGF-A and sVEGFR-1 levels and disease severity in patients diagnosed with COVID-19.</div></div><div><h3>Methods</h3><div>In this single-center observational study, 92 COVID-19 patients, classified into mild, moderate, and severe categories, and 29 healthy controls were enrolled. Serum VEGF-A and sVEGFR-1 levels were quantified using enzyme-linked immunosorbent assay (ELISA). Clinical, demographic, and laboratory data were collected. Statistical analyses included ANOVA, Kruskal-Wallis, Spearman correlation, logistic regression, and ROC curve analysis.</div></div><div><h3>Results</h3><div>Both VEGF-A and sVEGFR-1 levels were significantly lower in severe COVID-19 patients compared to controls (<em>p</em> &lt; 0.001). Negative correlations were observed between VEGF-A levels and disease severity (<em>r</em> = -0.55, <em>p</em> &lt; 0.001), and between sVEGFR-1 levels and severity (<em>r</em> = -0.48, <em>p</em> &lt; 0.001). Logistic regression analysis identified VEGF-A as an independent predictor of severe COVID-19 (OR = 0.964, <em>p</em> = 0.021). No significant differences in VEGF-A or sVEGFR-1 levels were found between survivors and non-survivors among the severe group.</div></div><div><h3>Conclusion</h3><div>Serum VEGF-A and sVEGFR-1 levels are inversely associated with COVID-19 disease severity, suggesting their potential role as early prognostic biomarkers. These findings underscore the importance of endothelial dysfunction in COVID-19 progression and encourage further research on angiogenic markers in viral infections.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117007"},"PeriodicalIF":2.1,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144662496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the BioFire® BCID2 panel on antimicrobial treatment and mortality in pediatric gram-negative bloodstream infections","authors":"Ilker Devrim ,&nbsp;Arife Ozer ,&nbsp;Deniz Ergun ,&nbsp;Hincal Ozbakir ,&nbsp;Berna Kahraman Cetin ,&nbsp;Ozlem Yilman ,&nbsp;Arzu Bayram ,&nbsp;Fahri Yüce Ayhan ,&nbsp;Tuba Hilkay Karaman ,&nbsp;Hasan Agin ,&nbsp;Nuri Bayram","doi":"10.1016/j.diagmicrobio.2025.117003","DOIUrl":"10.1016/j.diagmicrobio.2025.117003","url":null,"abstract":"<div><h3>Purpose</h3><div>Rapid molecular diagnostics, such as the BioFire® BCID2 Panel, may improve clinical outcomes by facilitating earlier pathogen identification and antimicrobial stewardship. This study evaluates the impact of BCID2 implementation on antimicrobial treatment and mortality in pediatric Gram-negative Bloodstream infections (BSI).</div></div><div><h3>Methods</h3><div>Pediatric patients with microbiologically confirmed Gram-negative BSI were divided into two groups: the pre-BCID2 group (diagnosed using conventional blood cultures) and the BCID2 group (diagnosed using the BCID2 Panel). Primary outcomes included time to pathogen identification and antimicrobial treatment modifications. Secondary outcomes included 7-day and 30-day mortality rates.</div></div><div><h3>Results</h3><div>A total of 97 Gram-negative BSI episodes were analyzed (pre-BCID2: 59, BCID2: 38). The BCID2 panel significantly reduced the time to appropriate antimicrobial therapy (median reduction: 55.1 h, <em>p</em> &lt; 0.01). Antimicrobial treatment was modified in 78.9 % of cases following BCID2 results, with 42.1 % requiring changes due to resistance gene detection. Glycopeptide use was discontinued in 28.9 %. The 7-day mortality rate was 10.5 % in the BCID2 group versus 8.5 % in the pre-BCID2 group (<em>p</em> &gt; 0.05).</div></div><div><h3>Conclusions</h3><div>The BCID2 panel significantly accelerated pathogen and resistance gene identification, leading to improved appropriate antimicrobial usage in pediatric Gram-negative BSI.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117003"},"PeriodicalIF":2.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Candida tropicalis in the diabetic urinary tract: Biofilm resistance, genomic plasticity, and public health implications","authors":"Rob E. Carpenter","doi":"10.1016/j.diagmicrobio.2025.117005","DOIUrl":"10.1016/j.diagmicrobio.2025.117005","url":null,"abstract":"<div><div>Fungal urinary tract infections (fUTIs) are emerging as a public health concern, notably in South Asia, where a convergence of ecological, genetic, and clinical factors underlies a rising burden of antifungal-resistant disease. This review synthesizes epidemiological, mechanistic, and genetic evidence implicating Candida tropicalis as a dominant uropathogen in South Asia’s diabetic and immunocompromised populations. We examine the shift from Candida albicans to non-albicans Candida (NAC) species, driven by selective antifungal pressure and nosocomial transmission. Emphasis is placed on the virulence and adaptability of C. tropicalis, which forms biofilms, adapts metabolically under glycosuric and hypoxic conditions, and expresses antifungal resistance genes such as ERG11, CDR1, MDR1, and FKS1. Concurrently, South Asian host populations exhibit genetic variants—e.g., in TLR4, CLEC7A, CYP2C19—that impair fungal recognition, immune clearance, and antifungal pharmacokinetics, creating a syndemic landscape. We detail biofilm-mediated resistance mechanisms, epigenetic regulation of virulence genes, and the role of environmental sensing pathways in adaptive pathogenesis. Furthermore, the review delineates clinical challenges posed by biofilm-associated infections, delayed diagnostics, and resistance underestimation. Finally, we propose a suite of public health and clinical recommendations—including biofilm-specific diagnostics, antifungal stewardship programs, pharmacogenomic screening, and national surveillance—to mitigate the escalating burden of drug-resistant candiduria. This integrative perspective bridges molecular pathogenesis and systems-level responses, offering a strategic roadmap for clinicians and policymakers to address C. tropicalis-driven fUTIs in South Asia and other high-risk regions.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117005"},"PeriodicalIF":2.1,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144623469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Loop-mediated isothermal amplification as a diagnostic tool for rapid identification of enteric bacterial pathogens from stool samples","authors":"Lisa Siegert,&nbsp;Sylvia Stoll,&nbsp;Birgit Edel,&nbsp;Bettina Löffler,&nbsp;Jürgen Rödel","doi":"10.1016/j.diagmicrobio.2025.117004","DOIUrl":"10.1016/j.diagmicrobio.2025.117004","url":null,"abstract":"<div><div>Molecular assays, which are commonly based on multiplex PCR techniques, are increasingly being used to diagnose bacterial gastroenteritis due to faster results and more straightforward workflows compared to conventional culture. Many culture-dependent methods and semi-automated PCR assays, are labour-intensive and require technical expertise. Therefore, assays that are easy to perform and allow for the timely identification of the most common enteric bacterial pathogens may be of interest. This study investigated a molecular assay based on loop-mediated isothermal amplification (LAMP) for the rapid identification of several common bacterial pathogens. A total of 204 stool samples were analysed. The sensitivity and specificity of the assay, compared to the BD MAX™ Enteric Bacterial Panel PCR as the reference method, were as follows: 88.35 % and 99.04 % for <em>Campylobacter</em> spp., 88 % and 100 % for <em>Salmonella</em> spp., and 71.43 % and 100 % for Shiga toxins (<em>stx</em>), respectively. Overall sensitivity of the LAMP assay was 89.81 % for samples with PCR Ct values ≤40, and 95.14 % when using a Ct cut-off ≤35, respectively. More samples tested positive for <em>C. jejuni, C. coli</em> and <em>stx1</em> by LAMP than by culture. There was 100 % concordance between the two methods for <em>stx2</em> and <em>Y. enterocolitica</em>. Four out of 25 <em>Salmonella</em> cases were identified by culture but not by LAMP. With a test run time of 30 min and a few minutes for sample preparation, the LAMP assay could be useful for diagnosing bacterial gastrointestinal pathogens in individual cases where specific therapeutic decisions are required.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117004"},"PeriodicalIF":2.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144656590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From misdiagnosis to precision therapy: A case of scedosporium apiospermum pneumonia in an immunocompetent host","authors":"Wei Tang ,&nbsp;Haiyan Xue ,&nbsp;XiaLin He ,&nbsp;Sha Lin ,&nbsp;Zhixiong Fang","doi":"10.1016/j.diagmicrobio.2025.117001","DOIUrl":"10.1016/j.diagmicrobio.2025.117001","url":null,"abstract":"<div><div><em>Scedosporium apiospermum</em>, a rare but increasingly recognized fungal pathogen, poses significant diagnostic and therapeutic challenges. Traditionally associated with immunocompromised individuals. We present a case of <em>S. apiospermum</em> lung disease in an immunocompetent patient, initially misdiagnosed as tuberculosis due to overlapping clinical and radiological features. Accurate diagnosis was achieved through bronchoscopy and fungal culture, leading to successful treatment with antifungal therapy. This case highlights the importance of considering <em>S. apiospermum</em> in the differential diagnosis of refractory lung infections, even in patients without obvious risk factors. Additionally, a brief literature review sheds light on the epidemiology, clinical presentation, and treatment strategies for this pathogen, emphasizing its clinical relevance and the need for heightened awareness. By showcasing this case, we aim to contribute to the understanding of <em>S. apiospermum</em> lung disease and its management, inspiring further research and improving patient outcomes.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117001"},"PeriodicalIF":2.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144634061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creation and validation of improved MALDI-TOF MS libraries for S. bovis-S. equinus-complex subspecies identification adapted to diagnostic culturing and extraction conditions","authors":"Jonas Öberg ,&nbsp;Agnes Engberg ,&nbsp;Malin Inghammar ,&nbsp;Bo Nilson","doi":"10.1016/j.diagmicrobio.2025.117000","DOIUrl":"10.1016/j.diagmicrobio.2025.117000","url":null,"abstract":"<div><h3>Objectives</h3><div>Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) libraries have limited capabilities for identification of <em>Streptococcus bovis/Streptococcus equinus</em>-complex (SBSEC) subspecies. The objective was to develop and validate novel MALDI-TOF MS libraries adapted to diagnostic culturing and sampling conditions for improved identification of SBSEC subspecies.</div></div><div><h3>Methods</h3><div>SBSEC isolates had previously been identified by whole genome sequencing, constituting the reference standard. Two libraries were constructed based on 53 isolates cultured on blood agar plates under aerobic conditions (SBSEC-CMRS-BAE) and on chocolate agar under anaerobic conditions (SBSEC<img>CMRS-CAN). The performances of the new libraries, the Bruker MALDI Biotyper (MBT) Compass Library and the previously developed SBSEC<img>CMRS library based on isolates cultured in brain heart infusion-broth, were validated with 119 unique isolates. Each isolate was sampled using the direct transfer, on-target extraction, and full extraction methods under the two different culture conditions – in total 714 different isolates and conditions.</div></div><div><h3>Results</h3><div>With a cutoff identification score of ≥2.0, the MBT compass library identified subspecies in 463/714 (65 %) in total for all culturing conditions and methods, while the broth-based SBSEC<img>CMRS library identified 674/698 (97 %). The novel SBSEC-CMRS-BAE and SBSEC<img>CMRS-CAN libraries identified subspecies in 707/713 (99 %) and 684/706 (97 %), respectively. The SBSEC-CMRS-BAE library performed best, regardless of the culturing conditions used or the three sample preparation methods employed, with up to 100 % correct subspecies identifications.</div></div><div><h3>Conclusions</h3><div>The novel SBSEC-CMRS-BAE library performed excellently and improved MALDI-TOF MS performance in identifying SBSEC subspecies. It can be implemented directly into routine clinical practice where the Bruker MALDI Biotyper is used.</div></div>","PeriodicalId":11329,"journal":{"name":"Diagnostic microbiology and infectious disease","volume":"113 3","pages":"Article 117000"},"PeriodicalIF":2.1,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144634060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}